Mostrando 10 resultados de: 14
Publisher
Drug Metabolism and Personalized Therapy(3)
Pharmacogenomics Journal(3)
Pharmacogenomics(2)
Clinical Pharmacology and Therapeutics(1)
Expert Opinion on Drug Metabolism and Toxicology(1)
An update on HLA alleles associated with adverse drug reactions
ReviewAbstract: Adverse drug reactions (ADRs) are considered as an important cause of morbidity and mortality. The hPalabras claves:abacavir, adverse drug reactions, Allopurinol, carbamazepine, human leukocyte antigen (HLA), hypersensitivity syndrome, pharmacogenetics, Stevens-Johnson syndromeAutores:Adrián LLerena, Fricke-Galindo I., López-López M.Fuentes:scopusCYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy
ArticleAbstract: We aimed to explore the possible influence of CYP2C9 (∗2, ∗3 and IVS8-109 A>T), CYP2C19 (∗2, ∗3 andPalabras claves:Autores:Adrián LLerena, Dorado P., Familiar-López I., Fricke-Galindo I., Jung-Cook H., López-López M., Martínez-Juárez I.E., Monroy-Jaramillo N., Ortega-Vázquez A., Penãs-Lledó E.M.Fuentes:scopusCarbamazepine adverse drug reactions
ReviewAbstract: Introduction: Carbamazepine (CBZ) is used for the treatment of epilepsy and other neurological and pPalabras claves:adverse drug reactions, carbamazepine, Hepatotoxicity, Hypersensitivity, hyponatremia, Stevens-Johnson syndrome, Teratogenesis, toxic epidermal necrolysisAutores:Adrián LLerena, Fricke-Galindo I., Jung-Cook H., López-López M.Fuentes:scopusAllele and genotype frequencies of genes relevant to anti-epileptic drug therapy in Mexican-Mestizo healthy volunteers
ArticleAbstract: Aim: To determine allele and genotype frequencies of genes influencing anti-epileptic drug therapy iPalabras claves:ABCC2, anti-epileptics, CYP3A5, EPHX1, GABRA1, HNF4A, Mexican-Mestizo, NR1I2, pharmacogenetics, RALBP1, SCN1A, SCN2A, UGT1A1, UGT2B7Autores:Adrián LLerena, Dorado P., Fricke-Galindo I., Jung-Cook H., López-López M., Monroy-Jaramillo N., Ortega-Vázquez A., Penãs-Lledó E.M.Fuentes:scopusGenomic Ancestry, CYP2D6, CYP2C9, and CYP2C19 Among Latin Americans
ArticleAbstract: We present the distribution of CYP2D6, CYP2C9, and CYP2C19 variants and pbkp_redicted phenotypes inPalabras claves:Autores:Adrián LLerena, Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Ferreiro V., Francisco J.López Hernández, Fricke-Galindo I., Galaviz-Hernandez C., Garza-Ocañas L., Gilman R.H., Grazina M., Humberto Fariñas, Jiménez-Arce G., Jung-Cook H., Lares-Aseff I., Lazalde-Ramos B.P., López-López M., Michelin L.A., Monroy-Jaramillo N., Moya G.E., Naranjo M.E.G., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rodrigues-Soares F., Rojas-Martinez A., Santiago Terán, Sarmiento A.P., Scliar M.O., Sosa-Macías M.G., Tarazona-Santos E.M., Tinoco C.A., Zamudio R.Fuentes:googlescopusNews in DMPT: Leaders in Pharmacogenetics Section
OtherAbstract:Palabras claves:Autores:Adrián LLerena, Fricke-Galindo I.Fuentes:scopusInfluence of genetic variants and antiepileptic drug co-treatment on lamotrigine plasma concentration in Mexican Mestizo patients with epilepsy
ArticleAbstract: Genetic and nongenetic factors may contribute to lamotrigine (LTG) plasma concentration variabilityPalabras claves:Autores:Adrián LLerena, Dorado P., Fricke-Galindo I., Jung-Cook H., López-López M., Martínez-Juárez I.E., Monroy-Jaramillo N., Ortega-Vázquez A., Penãs-Lledó E.M., Rojas-Tomé I.S.Fuentes:scopusInterethnic variability in CYP2D6, CYP2C9, and CYP2C19 genes and pbkp_redicted drug metabolism phenotypes among 6060 ibero-and native Americans: RIBEF-CEIBA consortium report on population pharmacogenomics
ArticleAbstract: Pharmacogenetic variation in Latin Americans is understudied, which sets a barrier for the goal of gPalabras claves:Amerindians, CYP2C19, CYP2C9, CYP2D6, drug metabolism, LATIN AMERICANS, pharmacogenetics, Precision MedicineAutores:Adrián LLerena, Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Fcrreiro V., Francisco J.López Hernández, Fricke-Galindo I., Galaviz-Hernandez C., Garza-Ocañas L., Gilman R.H., Gouveia M.H., Grazina M., Humberto Fariñas, Jiménez-Arce G., Jung-Cook H., Lares-Aseff I., Lazalde-Ramos B.P., López-López M., Monroy-Jaramillo N., Moya G.E., Naranjo M.E.G., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rodrigues-Soares F., Rojas-Martinez A., Santiago Terán, Sarmiento A.P., Scliar M.O., Sosa-Macías M.G., Tarazona-Santos E.M., Tinoco C.A., Zamudio R.Fuentes:googlescopusInterethnic variability of pharmacogenetic biomarkers in Mexican healthy volunteers: A report from the RIBEF (Ibero-American Network of Pharmacogenetics and Pharmacogenomics)
ReviewAbstract: Mexico presents a complex population diversity integrated by Mexican indigenous (MI) (7% of Mexico'sPalabras claves:drug metabolizing enzymes, drug receptors, drug transporters, Mexicans, pharmacogeneticsAutores:Adrián LLerena, Fricke-Galindo I., Jung-Cook H., López-López M.Fuentes:scopusInterethnic variation of CYP2C19 alleles, 'pbkp_redicted' phenotypes and 'measured' metabolic phenotypes across world populations
ReviewAbstract: The present study evaluates the worldwide frequency distribution of CYP2C19 alleles and CYP2C19 metaPalabras claves:Autores:Adrián LLerena, Céspedes-Garro C., de Andrés F., Delgado A., Fricke-Galindo I., López-López M., Naranjo M.E.G., Penãs-Lledó E.M., Rodrigues-Soares F.Fuentes:scopus